Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Sun Pharmaceutical, Teva, Pfizer, Takeda gastrointestinal news

Teva and Sun will pay $2.2 billion to Pfizer and Takeda to settle litigation related to the validity of a patent owned

Read the full 227 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE